Literature DB >> 9333264

Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12.

M A Pericak-Vance1, M P Bass, L H Yamaoka, P C Gaskell, W K Scott, H A Terwedow, M M Menold, P M Conneally, G W Small, J M Vance, A M Saunders, A D Roses, J L Haines.   

Abstract

CONTEXT: Four genetic loci have been identified as contributing to Alzheimer disease (AD), including the amyloid precursor protein gene, the presenilin 1 gene, the presenilin 2 gene, and the apolipoprotein E gene, but do not account for all the genetic risk for AD.
OBJECTIVE: To identify additional genetic risk factors for late-onset AD.
DESIGN: A complete genomic screen was performed (N=280 markers). Critical values for chromosomal regional follow-up were a P value of .05 or less for affected relative pair analysis or sibpair analysis, a parametric lod score of 1.0 or greater, or both. Regional follow-up included analysis of additional markers and a second data set.
SETTING: Clinic populations in the continental United States. PATIENTS: From a series of multiplex families affected with late-onset (> or =60 years) AD ascertained during the last 14 years (National Insititute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association diagnostic criteria) and for which DNA has been obtained, a subset of 16 families (135 total family members, 52 of whom were patients with AD) was used for the genomic screen. A second subset of 38 families (216 total family members, 89 of whom were patients with AD) was used for the follow-up analysis. MAIN OUTCOME MEASURES: Linkage analysis results generated using both genetic model-dependent (lod score) and model-independent methods.
RESULTS: Fifteen chromosomal regions warranted initial follow-up. Follow-up analyses revealed 4 regions of continued interest on chromosomes 4, 6, 12, and 20, with the strongest results observed forchromosome 12. Peak 2-point affecteds-only lod scores (n=54) were 1.3, 1.6, 2.7, and 2.2 and affected relative pairs P values (n=54) were .04, .03, .14, and .04 for D12S373, D12S1057, D12S1042, and D12S390, respectively. Sibpair analysis (n=54) resulted in maximum lod scores (MLSs) of 1.5, 2.6, 3.2, and 2.3 for these markers, with a peak multipoint MLS of 3.5. A priori stratification by APOE genotype identified 27 families that had at least 1 member with AD whose genotype did not contain an APOE*4 allele. Analysis of these 27 families resulted in MLSs of 1.0, 2.4, 3.7, and 3.3 and a peak multipoint MLS of 3.9.
CONCLUSIONS: A complete genomic screen in families affected with late-onset AD identified 4 regions of interest after follow-up. Chromosome 12 gave the strongest and most consistent results with a peak multipoint MLS of 3.5, suggesting that this region contains a new susceptibility gene for AD. Additional analyses are necessary to identify the chromosome 12 susceptibility gene for AD and to follow up the regions of interest on chromosomes 4, 6, and 20.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333264

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  68 in total

Review 1.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

2.  Genomewide scans of complex human diseases: true linkage is hard to find.

Authors:  J Altmüller; L J Palmer; G Fischer; H Scherb; M Wjst
Journal:  Am J Hum Genet       Date:  2001-09-14       Impact factor: 11.025

Review 3.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

4.  A genome-wide linkage analysis of dementia in the Amish.

Authors:  Daniel W Hahs; Jacob L McCauley; Amy E Crunk; Lynne L McFarland; Perry C Gaskell; Lan Jiang; Susan H Slifer; Jeffery M Vance; William K Scott; Kathleen A Welsh-Bohmer; Stephanie R Johnson; Charles E Jackson; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-03-05       Impact factor: 3.568

5.  Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.

Authors:  Cyrus P Zabetian; Chris J Lauricella; Debby W Tsuang; James B Leverenz; Gerard D Schellenberg; Haydeh Payami
Journal:  Arch Neurol       Date:  2006-01

6.  Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data.

Authors:  Richard Sherva; Clinton T Baldwin; Rivka Inzelberg; Badri Vardarajan; L Adrienne Cupples; Kathryn Lunetta; Abdalla Bowirrat; Adam Naj; Margaret Pericak-Vance; Robert P Friedland; Lindsay A Farrer
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease.

Authors:  Jennifer Williamson; Susan LaRusse
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

Review 8.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

9.  Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2.

Authors:  Ellen M Wijsman; E Warwick Daw; Change-En Yu; Haydeh Payami; Ellen J Steinbart; David Nochlin; Erin M Conlon; Thomas D Bird; Gerard D Schellenberg
Journal:  Am J Hum Genet       Date:  2004-07-08       Impact factor: 11.025

10.  Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics.

Authors:  J H Lee; R Mayeux; D Mayo; J Mo; V Santana; J Williamson; A Flaquer; A Ciappa; H Rondon; P Estevez; R Lantigua; T Kawarai; A Toulina; M Medrano; M Torres; Y Stern; B Tycko; E Rogaeva; P St George-Hyslop; J A Knowles
Journal:  Mol Psychiatry       Date:  2004-11       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.